caa a22 4500 465790062 CHVBK 20180323112021.0 cr unu---uuuuu 170327e19900501xx s 000 0 eng 10.1007/BF00177260 doi (NATIONALLICENCE)springer-10.1007/BF00177260 Evaluation of carboplatin (NSC 241240) in patients with recurrent or metastatic renal cell carcinoma [Elektronische Daten] [Donald Trump, Paul Elson] Summary: Eighteen evaluable patients with metastatic or recurrent renal cell carcinoma were treated with carboplatin. Fourteen patients received 400 mg/m2 as the initial dose, and four patients received reduced doses based on prior radiation therapy and/or elevated serum creatinine. No responses were seen. Median survival of these 18 patients was 8.3 months. Risk group status which previously has been identified as an important indicator of survival was predictive for survival in this study. Patients in the most favorable risk groups had a median survival of 21.2 months vs. 6.6 months for the most unfavorable risk groups. No lethal toxicities occurred with the administration of carboplatin; however, 66% of patients received doses of sufficient magnitude to cause severe or life threatening thrombocytopenia or anemia. Kluwer Academic Publishers, 1990 renal cell carcinoma nationallicence carboplatin nationallicence Trump Donald University of Wisconsin Clinical Cancer Center, (CA-21076), Madison, WI, USA aut Elson Paul Dana-Farber Cancer Institute, Harvard School of Public Health, (CA-23318), Boston, MA, USA aut Investigational New Drugs Kluwer Academic Publishers 8/2(1990-05-01), 201-203 0167-6997 8:2<201 1990 8 10637 https://doi.org/10.1007/BF00177260 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00177260 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Trump Donald University of Wisconsin Clinical Cancer Center, (CA-21076), Madison, WI, USA aut NATIONALLICENCE 700 1- Elson Paul Dana-Farber Cancer Institute, Harvard School of Public Health, (CA-23318), Boston, MA, USA aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8/2(1990-05-01), 201-203 0167-6997 8:2<201 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer